Literature DB >> 19399877

Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats.

Kathy Steece-Collier1, Katherine E Soderstrom, Timothy J Collier, Caryl E Sortwell, Eleonora Maries-Lad.   

Abstract

Clinical trials of neural grafting for Parkinson's disease (PD) have produced variable, but overall disappointing, results. One particular disappointment has been the development of aberrant motor complications following dopamine (DA) neuron grafting. Despite a lack of consistent benefit, the utility of dopamine neuron replacement remains supported by clinical and basic data. In a continued effort to elucidate factors that might improve this therapy, we used a parkinsonian rat model to examine whether pregraft chronic levodopa affected graft efficacy and/or graft-induced dyskinesia (GID) induction. Indeed, all grafted PD patients to date have had a pregraft history of long-term levodopa. It is well established that long-term levodopa results in a plethora of long-lasting neurochemical alterations and genomic changes indicative of altered structural and synaptic plasticity. Thus, therapeutic dopamine terminal replacement in a striatal environment complicated by such changes could be expected to lead to abnormal or inappropriate connections between graft and host brain and to contribute to suboptimal efficacy and/or postgraft GID behaviors. To investigate the effect of pregraft levodopa, one group of parkinsonian rats received levodopa for 4 weeks prior to grafting. A second levodopa-naïve group was grafted, and the grafts were allowed to mature for 9 weeks prior to introducing chronic levodopa. We report here that, in parkinsonian rats, preexposure to chronic levodopa significantly reduces behavioral and neurochemical efficacy of embryonic dopamine grafts. Furthermore, dopamine terminal replacement prior to introduction of chronic levodopa is highly effective at preventing development of levodopa-induced dyskinesias, and GID-like behaviors occur regardless of pregraft levodopa status. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399877      PMCID: PMC2886671          DOI: 10.1002/cne.22037

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  55 in total

Review 1.  Molecular effects of dopamine on striatal-projection pathways.

Authors:  C R Gerfen
Journal:  Trends Neurosci       Date:  2000-10       Impact factor: 13.837

Review 2.  Pathophysiology of the basal ganglia in Parkinson's disease.

Authors:  J A Obeso; M C Rodríguez-Oroz; M Rodríguez; J L Lanciego; J Artieda; N Gonzalo; C W Olanow
Journal:  Trends Neurosci       Date:  2000-10       Impact factor: 13.837

Review 3.  The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.

Authors:  O Rascol
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

4.  Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.

Authors:  D A Di Monte; A McCormack; G Petzinger; A M Janson; M Quik; W J Langston
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

5.  Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias.

Authors:  G E Meredith; I E De Souza; T M Hyde; G Tipper; M L Wong; M F Egan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

6.  The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.

Authors:  K E Soderstrom; G Meredith; T B Freeman; S O McGuire; T J Collier; C E Sortwell; Qun Wu; K Steece-Collier
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

7.  Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.

Authors:  I Strömberg; J Kehr; B Andbjer; K Fuxe
Journal:  Exp Neurol       Date:  2000-07       Impact factor: 5.330

8.  Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Authors:  C S Lee; M A Cenci; M Schulzer; A Björklund
Journal:  Brain       Date:  2000-07       Impact factor: 13.501

Review 9.  Molecular basis of levodopa-induced dyskinesias.

Authors:  F Calon; R Grondin; M Morissette; M Goulet; P J Blanchet; T Di Paolo; P J Bédard
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

10.  Intrastriatal implants of mesencephalic cell suspensions in weaver mutant mice: ultrastructural relationships of dopaminergic dendrites and axons issued from the graft.

Authors:  L C Triarhou; P Brundin; G Doucet; J Norton; A Björklund; B Ghetti
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

View more
  15 in total

1.  Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat.

Authors:  Jeffrey H Kordower; Hemraj B Dodiya; Adam M Kordower; Brian Terpstra; Katrina Paumier; Lalitha Madhavan; Caryl Sortwell; Kathy Steece-Collier; Timothy J Collier
Journal:  Neurobiol Dis       Date:  2011-05-12       Impact factor: 5.996

2.  A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.

Authors:  Christopher A Lieu; Allen R Kunselman; Bala V Manyam; Kala Venkiteswaran; Thyagarajan Subramanian
Journal:  Parkinsonism Relat Disord       Date:  2010-05-31       Impact factor: 4.891

3.  Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.

Authors:  Kathy Steece-Collier; Timothy J Collier; Jack W Lipton; Jennifer A Stancati; Mary E Winn; Allyson Cole-Strauss; Rhyomi Sellnow; Melissa M Conti; Natosha M Mercado; Eduardo A Nillni; Caryl E Sortwell; Fredric P Manfredsson; Christopher Bishop
Journal:  Exp Neurol       Date:  2020-05-05       Impact factor: 5.330

4.  Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum.

Authors:  Kathy Steece-Collier; David J Rademacher; Katherine Soderstrom
Journal:  Basal Ganglia       Date:  2012-02-11

5.  The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.

Authors:  Vishakh Iyer; Kala Venkiteswaran; Sandip Savaliya; Christopher A Lieu; Erin Handly; Timothy P Gilmour; Allen R Kunselman; Thyagarajan Subramanian
Journal:  Neurobiol Dis       Date:  2021-08-27       Impact factor: 5.996

6.  Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses.

Authors:  Yiyue Zhang; Gloria E Meredith; Nasya Mendoza-Elias; David J Rademacher; Kuei Y Tseng; Kathy Steece-Collier
Journal:  J Neurosci       Date:  2013-07-10       Impact factor: 6.167

Review 7.  Cell therapy for Parkinson's disease is coming of age: current challenges and future prospects with a focus on immunomodulation.

Authors:  Shirley D Wenker; Fernando J Pitossi
Journal:  Gene Ther       Date:  2019-04-16       Impact factor: 5.250

Review 8.  Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?

Authors:  Daniella Rylander Ottosson; Emma Lane
Journal:  Front Cell Neurosci       Date:  2016-02-08       Impact factor: 5.505

9.  Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease.

Authors:  Ludivine S Breger; Korbinian Kienle; Gaynor A Smith; Stephen B Dunnett; Emma L Lane
Journal:  Brain Behav Immun       Date:  2016-11-15       Impact factor: 7.217

Review 10.  Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia.

Authors:  Elisabetta Tronci; Camino Fidalgo; Manolo Carta
Journal:  Parkinsons Dis       Date:  2015-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.